RxDoctor Payments DataLook up a doctor →

Huy Tran, MD

Gastroenterology · Orlando, FLNPI 1699082149

Payments from drug & device makers

$1,231,221in general payments, 2019–2025

Across 169 payments — averaging $7285.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$392K
  • Bristol Myers Squibb$340K
  • Takeda Pharmaceuticals U.S.A., Inc.$186K
  • Pfizer$143K
  • AbbVie$44K
  • Alnylam Pharmaceuticals Inc.$39K
  • plus $87K from 14 others

What the payments were for

  • Food & beverage$87698%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,231,221 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$76,368
Medicare patients
261
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide67$44,855
XifaxanRifaximin11$27,943
TrulancePlecanatide17$12,949
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates39$2,428
Lubiprostone18$2,250
Omeprazole175$2,024
Mirtazapine25$577
Pantoprazole Sodium32$489
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$380
Gabapentin12$88
Buspirone Hcl11$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$44,302$44,85567 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$25$40,89228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →